Hepatic trisegmentectomy for hepatoblastoma in a 3-year-old patient. Case report
Article Sidebar
Main Article Content
Abstract
Introduction: Liver cancer in children, mainly hepatoblastoma, is uncommon, but accounts for approximately 1-2% of all childhood cancers. Although it is the most common primary liver cancer in children, its five-year survival rate is low due to resistance to chemotherapy in 20% of cases. The annual incidence in children under 1 year is 11.2 cases per million. Hepatoblastoma tends to affect white children more and is more common in boys than in girls, especially before the age of 5. Clinical case: A female patient with an upper respiratory condition, with no significant history, whose physical examination detects hepatomegaly without other accompanying symptoms, it is decided to perform complementary examinations to reach the diagnosis. Evolution Patient: with hepatomegaly, laboratory tests are performed and abdominal ultrasound shows rounded formations in liver without vascularization. A diagnostic laparoscopy was performed and a solid tumor mass was removed from segment IV of the liver and the sickle ligament. Histopathological analyses revealed hepatoblastoma Follow-up examinations showed decrease of tumor markers and postoperative changes in the surgical bed. Conclusion: Initial surgery in children with stage III and IV hepatoblastoma is considered safe and feasible, with the potential to reduce the total amount of chemotherapy needed and its side effects. When the tumors are completely resected, there is a possibility of long-term survival without the need for chemotherapy.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Herzog CE, Andrassy RJ, Eftekhari F. Childhood Cancers: Hepatoblastoma. The Oncologist. 1 de diciembre de 2000;5(6):445-53.
Devi LP, Kumar R, Handique A, Kumar M. Hepatoblastoma—a Rare Liver Tumor with Review of Literature. J Gastrointest Cancer. 1 de diciembre de 2014;45(1):261-4.
Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, et al. Risk- stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol. enero de 2017;18(1):122-31.
Pediatric Hepatoblastoma: Practice Essentials, Background, Pathophysiology. 9 de diciembre de 2021; Disponible en: https://emedicine.medscape.com/article/986802-overview?form=fpf
Ng K, Mogul DB. Pediatric Liver Tumors. Clin Liver Dis. 1 de noviembre de 2018;22(4):753-72.
Czauderna P, Garnier H. Hepatoblastoma: current understanding, recent advances, and controversies. F1000Research. 15 de enero de 2018;7:53.
Wu X, Wang J, Duan Y, Liu Y, Liu Y, Chen X, et al. Surgical resection of pediatric PRETEXT III and IV hepatoblastoma: A retrospective study investigating the need for preoperative chemotherapy. Front Pediatr. 2022;10:878095.
Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2020;23(2):79-95.
Kim PH, Shin HJ, Yoon HM, Choi YH, Namgoong JM, Kim DY, et al. Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) System for Pediatric Patients with Hepatoblastoma: A Retrospective, Hospital-Based Cohort Study in South Korea. Cancer Res Treat Off J Korean Cancer Assoc. enero de 2022;54(1):253-8.
Meyers RL, Czauderna P, Otte JB. Surgical treatment of hepatoblastoma. Pediatric Blood & Cancer. 2012 Nov; 59(5): p. 800-808.
Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. febrero de 2014;26(1):29.
Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O’Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children’s Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):719-727. doi: 10.1016/S1470-2045(18)30895-7. Epub 2019 Apr 8. Erratum in: Lancet Oncol. 2019 May;20(5):e243. doi: 10.1016/S1470-2045(19)30243-8. PMID: 30975630; PMCID: PMC6499702.
Trobaugh-Lotrario AD, Katzenstein HM. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies. Pediatr Blood Cancer. noviembre de 2012;59(5):809-12.
Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer DF, Lindenfeld L, Meza J, Neuwelt EA, Pollock BH, Sung L. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children’s Oncology Group. J Clin Oncol. 2017 Feb;35(4):440-445. doi: 10.1200/JCO.2016.69.2319. Epub 2016 Dec 12. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1141. doi: 10.1200/JCO.2017.72.7685. PMID: 27937095; PMCID: PMC5455699.
Dicken BJ, Bigam DL, Lees GM. Association between surgical margins and long- term outcome in advanced hepatoblastoma. J Pediatr Surg. 1 de mayo de 2004;39(5):721-5.